Spots Global Cancer Trial Database for peripheral blood stem cell

Every month we try and update this database with for peripheral blood stem cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy	NCT02143830	Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno...	Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo...	3 Months -	Children's Hospital Medical Center, Cincinnati
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS	NCT00025662	Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease	RFT5-SMPT-dgA Isolex system	18 Years - 75 Years	National Institutes of Health Clinical Center (CC)
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS	NCT00025662	Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease	RFT5-SMPT-dgA Isolex system	18 Years - 75 Years	National Institutes of Health Clinical Center (CC)
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells	NCT00023491	Graft vs Host D... Sjogren's Syndr...		-	National Institutes of Health Clinical Center (CC)
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy	NCT02143830	Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno...	Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo...	3 Months -	Children's Hospital Medical Center, Cincinnati
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: